Genome-wide identification of m 6 A-associated single nucleotide polymorphisms in complex diseases of nervous system

Fei Guo,Jingxuan Kang,Jing Xu,Siyu Wei,Junxian Tao,Yu Dong,Yingnan Ma,Hongsheng Tian,Xuying Guo,Shuo Bi,Chen Zhang,Hongchao Lv,Zhenwei Shang,Yongshuai Jiang,Mingming Zhang
DOI: https://doi.org/10.1016/j.neulet.2023.137513
IF: 3.197
2023-10-12
Neuroscience Letters
Abstract:N6-methyladenosine (m 6 A) is one of the most abundant chemical modifications on RNA and can affect the occurrence and development of diseases. Some studies have shown that the expressions of some m 6 A-related genes are significantly regulated by single nucleotide variants (SNV). However, the function of m 6 A-associated single nucleotide polymorphisms (m 6 A-SNP) remains unclear in multiple sclerosis (MS), Alzheimer's disease (AD) and Parkinson's disease (PD). Here, we identified the disease-associated m 6 A-SNPs by integrating genome-wide association study (GWAS) and m 6 A-SNPs from the RMVar database, and confirmed the relationship between these identified m 6 A-SNPs and their target genes in eQTL analysis and gene differential expression analysis. Finally, 26 genes corresponding to 20 m 6 A-SNPs with eQTL signals were identified and differentially expressed ( P < 0.05) in MS, 15 genes corresponding to 12 m 6 A-SNPs ( P < 1e-04) and were differentially expressed in AD, and 27 PD-associated m 6 A-SNPs regulated the expression of 31 genes. There were 5 HLA genes with eQTL signals ( HLA-DQB1, HLA-DRB1, HLA-DQA1, HLA-DQA2 and HLA-DQB1-AS1 ) in the three diseases. In summary, our study provided new insights into understanding the potential roles of these m 6 A-SNPs in disease pathogenesis as well as therapeutic target.
neurosciences
What problem does this paper attempt to address?